WallStreetZenWallStreetZen

NASDAQ: EFTR
Effector Therapeutics Inc Stock

$1.37+0.02 (+1.48%)
Updated Jun 13, 2024
EFTR Price
$1.37
Fair Value Price
N/A
Market Cap
$6.45M
52 Week Low
$1.19
52 Week High
$28.25
P/E
-0.11x
P/B
7.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.63M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
31.81
Operating Cash Flow
-$29M
Beta
0.99
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

EFTR Overview

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cancer treatments. Its lead product candidates are Tomivosertib and Zotatifin. It has a collaboration agreement with Pfizer Inc. eFFECTOR Therapeutics was founded in 2012 and is headquartered in Solana Beach, CA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EFTR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EFTR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EFTR is poor value based on its book value relative to its share price (7.79x), compared to the US Biotechnology industry average (6.3x)
P/B vs Industry Valuation
EFTR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EFTR due diligence checks available for Premium users.

Be the first to know about important EFTR news, forecast changes, insider trades & much more!

EFTR News

Valuation

EFTR fair value

Fair Value of EFTR stock based on Discounted Cash Flow (DCF)
Price
$1.37
Fair Value
-$2.09
Undervalued by
165.56%
EFTR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EFTR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.11x
Industry
-7.95x
Market
30.48x

EFTR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.79x
Industry
6.3x
EFTR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EFTR's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.8M
Profit Margin
0%
EFTR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$27.1M
Liabilities
$26.3M
Debt to equity
31.81
EFTR's short-term assets ($26.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EFTR's short-term assets ($26.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EFTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.3M
Investing
-$6.3M
Financing
$14.2M
EFTR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EFTR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
EFTR$6.45M+1.48%-0.11x7.79x
KZIA$6.38M-3.20%-0.66x1.84x
HEPA$6.51M+0.85%-0.13x0.87x
TTNP$6.34M0.00%-1.08x1.04x
TENX$6.27M-2.44%-0.13x0.50x

Effector Therapeutics Stock FAQ

What is Effector Therapeutics's quote symbol?

(NASDAQ: EFTR) Effector Therapeutics trades on the NASDAQ under the ticker symbol EFTR. Effector Therapeutics stock quotes can also be displayed as NASDAQ: EFTR.

If you're new to stock investing, here's how to buy Effector Therapeutics stock.

What is the 52 week high and low for Effector Therapeutics (NASDAQ: EFTR)?

(NASDAQ: EFTR) Effector Therapeutics's 52-week high was $28.25, and its 52-week low was $1.19. It is currently -95.15% from its 52-week high and 15.13% from its 52-week low.

How much is Effector Therapeutics stock worth today?

(NASDAQ: EFTR) Effector Therapeutics currently has 4,704,409 outstanding shares. With Effector Therapeutics stock trading at $1.37 per share, the total value of Effector Therapeutics stock (market capitalization) is $6.45M.

Effector Therapeutics stock was originally listed at a price of $260.00 in Jan 8, 2021. If you had invested in Effector Therapeutics stock at $260.00, your return over the last 3 years would have been -99.47%, for an annualized return of -82.6% (not including any dividends or dividend reinvestments).

How much is Effector Therapeutics's stock price per share?

(NASDAQ: EFTR) Effector Therapeutics stock price per share is $1.37 today (as of Jun 13, 2024).

What is Effector Therapeutics's Market Cap?

(NASDAQ: EFTR) Effector Therapeutics's market cap is $6.45M, as of Jun 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Effector Therapeutics's market cap is calculated by multiplying EFTR's current stock price of $1.37 by EFTR's total outstanding shares of 4,704,409.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.